A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder
PE+topiramate was associated with a greater reduction in PTSD symptoms than PE+placebo during active treatment. The addition of topiramate led to more rapid and pronounced PTSD symptom reduction, which may be of benefit to patients. Because effects of topiramate were not maintained at longer-term follow-up, extending time on topiramate or additional strategies to prolong such effects may be useful. Topiramate did not show added benefit to PE for percent heavy drinking days or secondary outcomes.
Authors
- Arthur L. Brody (ORCID: https://orcid.org/0000-0003-2614-8495)
- Robert M. Anthenelli (ORCID: https://orcid.org/0000-0002-6612-1126)
- Paula P. Schnurr (ORCID: https://orcid.org/0000-0002-6195-716X)
- Kaitlyn E. Panza (ORCID: https://orcid.org/0000-0003-1261-0239)
- Brian Martis
- Matthew T. Luciano (ORCID: https://orcid.org/0000-0003-4593-0001)
- Sonya B. Norman (ORCID: https://orcid.org/0000-0002-4751-1882)
- Steven L. Batki (ORCID: https://orcid.org/0000-0002-4950-4563)
- Tracy L. Simpson (ORCID: https://orcid.org/0000-0002-3333-9735)
- Michelle Lyons
- Katharine Lacefield
- Abigail C. Angkaw (ORCID: https://orcid.org/0000-0002-3703-4226)
- Brittany Davis (ORCID: https://orcid.org/0000-0001-9145-2632)
- Scott C. Matthews
- Moira Haller
Institutions
- VA San Diego Healthcare System (US)
Publication Details
- Journal
- American Journal of Psychiatry
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1176/appi.ajp.20240470
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00